SG11201408323RA - Prophylactic and/or therapeutic agent for mild cognitive impairment - Google Patents
Prophylactic and/or therapeutic agent for mild cognitive impairmentInfo
- Publication number
- SG11201408323RA SG11201408323RA SG11201408323RA SG11201408323RA SG11201408323RA SG 11201408323R A SG11201408323R A SG 11201408323RA SG 11201408323R A SG11201408323R A SG 11201408323RA SG 11201408323R A SG11201408323R A SG 11201408323RA SG 11201408323R A SG11201408323R A SG 11201408323RA
- Authority
- SG
- Singapore
- Prior art keywords
- prophylactic
- therapeutic drug
- cognitive impairment
- mild cognitive
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient 5 clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-( 1-cyclohexyl-l I l-tetra/ole-5-yl)butoxy]3.4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in drainage a pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of 10 a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Down's syndrome, or macular degeneration. 48
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012135906 | 2012-06-15 | ||
| JP2012223580 | 2012-10-05 | ||
| PCT/JP2013/003740 WO2013187075A1 (en) | 2012-06-15 | 2013-06-14 | Prophylactic and/or therapeutic agent for mild cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408323RA true SG11201408323RA (en) | 2015-01-29 |
Family
ID=49757918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408323RA SG11201408323RA (en) | 2012-06-15 | 2013-06-14 | Prophylactic and/or therapeutic agent for mild cognitive impairment |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20150152084A1 (en) |
| EP (1) | EP2862572B1 (en) |
| JP (2) | JP5715303B2 (en) |
| KR (1) | KR20150027800A (en) |
| CN (1) | CN104519884A (en) |
| AU (1) | AU2013275628A1 (en) |
| BR (1) | BR112014031154A2 (en) |
| CA (1) | CA2876371A1 (en) |
| IL (1) | IL236226A0 (en) |
| MX (1) | MX2014015310A (en) |
| RU (1) | RU2015101100A (en) |
| SG (1) | SG11201408323RA (en) |
| WO (1) | WO2013187075A1 (en) |
| ZA (1) | ZA201409134B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150027800A (en) * | 2012-06-15 | 2015-03-12 | 고에키 자이단 호징 센탄 이료 신코 자이단 | Prophylactic and/or therapeutic agent for mild cognitive impairment |
| JP2018538344A (en) * | 2015-12-25 | 2018-12-27 | 大塚製薬株式会社 | Medicine using aripiprazole and cilostazol |
| CN109310688B (en) * | 2016-05-19 | 2023-09-01 | 国立研究开发法人国立循环器病研究中心 | Medicine for preventing and/or treating dementia |
| JP6501425B2 (en) * | 2017-05-31 | 2019-04-17 | 学校法人藤田学園 | Aβ removal system |
| US20230270737A1 (en) * | 2020-05-11 | 2023-08-31 | Shimadzu Corporation | Therapeutic Agent for Mild Cognitive Impairment |
| WO2022270663A1 (en) * | 2021-06-23 | 2022-12-29 | 동아에스티 주식회사 | Pharmaceutical composition comprising donepezil, cilostazol, and aripiprazole for prevention, alleviation, or treatment of dementia, cognitive impairment, or vascular depression |
| WO2024054201A1 (en) * | 2022-09-06 | 2024-03-14 | The Johns Hopkins University | OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090149479A1 (en) | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
| WO2008030209A2 (en) * | 2005-05-23 | 2008-03-13 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor |
| US20100247636A1 (en) | 1998-11-02 | 2010-09-30 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising nilvadipine |
| US20090297597A1 (en) | 1998-11-02 | 2009-12-03 | Gary Liversidge | Modified Release Ticlopidine Compositions |
| DE69939748D1 (en) | 1998-11-02 | 2008-11-27 | Elan Pharma Int Ltd | MULTIPARTIC COMPOSITION OF METHYLPHENIDATE WITH MODIFIED RELEASE |
| US20080113025A1 (en) | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| US20080118556A1 (en) | 1998-11-02 | 2008-05-22 | Elan Corporation, Plc | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone |
| US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| US20070160675A1 (en) | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
| US20080102121A1 (en) | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US20090297602A1 (en) | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
| US20070122481A1 (en) | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
| TWI323660B (en) | 2003-02-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Pten inhibitor or maxi-k channels opener |
| WO2006132752A1 (en) | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
| WO2007037790A2 (en) | 2005-06-08 | 2007-04-05 | Elan Corporation, Plc | Modified release famciclovir compositions |
| CA2687289C (en) | 2007-05-22 | 2015-09-15 | Otsuka Pharmaceutical Co., Ltd. | A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease |
| AU2010249015A1 (en) * | 2009-05-15 | 2011-11-24 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| NZ600421A (en) | 2009-12-15 | 2014-06-27 | Metabolic Solutions Dev Co Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| KR20150027800A (en) * | 2012-06-15 | 2015-03-12 | 고에키 자이단 호징 센탄 이료 신코 자이단 | Prophylactic and/or therapeutic agent for mild cognitive impairment |
-
2013
- 2013-06-14 KR KR1020157001022A patent/KR20150027800A/en not_active Application Discontinuation
- 2013-06-14 CN CN201380031661.4A patent/CN104519884A/en active Pending
- 2013-06-14 AU AU2013275628A patent/AU2013275628A1/en not_active Abandoned
- 2013-06-14 WO PCT/JP2013/003740 patent/WO2013187075A1/en active Application Filing
- 2013-06-14 CA CA2876371A patent/CA2876371A1/en not_active Abandoned
- 2013-06-14 SG SG11201408323RA patent/SG11201408323RA/en unknown
- 2013-06-14 BR BR112014031154A patent/BR112014031154A2/en not_active IP Right Cessation
- 2013-06-14 EP EP13803699.1A patent/EP2862572B1/en not_active Not-in-force
- 2013-06-14 US US14/407,692 patent/US20150152084A1/en not_active Abandoned
- 2013-06-14 MX MX2014015310A patent/MX2014015310A/en unknown
- 2013-06-14 JP JP2014520940A patent/JP5715303B2/en not_active Expired - Fee Related
- 2013-06-14 RU RU2015101100A patent/RU2015101100A/en not_active Application Discontinuation
-
2014
- 2014-12-11 ZA ZA2014/09134A patent/ZA201409134B/en unknown
- 2014-12-14 IL IL236226A patent/IL236226A0/en unknown
-
2015
- 2015-03-12 JP JP2015049442A patent/JP6188737B2/en not_active Expired - Fee Related
- 2015-09-21 US US14/860,057 patent/US9737524B2/en active Active
-
2017
- 2017-07-14 US US15/650,554 patent/US10016409B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015110665A (en) | 2015-06-18 |
| EP2862572A4 (en) | 2015-11-04 |
| JP6188737B2 (en) | 2017-08-30 |
| CA2876371A1 (en) | 2013-12-19 |
| ZA201409134B (en) | 2015-12-23 |
| KR20150027800A (en) | 2015-03-12 |
| BR112014031154A2 (en) | 2017-08-08 |
| US9737524B2 (en) | 2017-08-22 |
| US20150152084A1 (en) | 2015-06-04 |
| JP5715303B2 (en) | 2015-05-07 |
| EP2862572B1 (en) | 2018-11-28 |
| AU2013275628A1 (en) | 2015-01-29 |
| RU2015101100A (en) | 2016-08-10 |
| WO2013187075A1 (en) | 2013-12-19 |
| US20170312265A1 (en) | 2017-11-02 |
| EP2862572A1 (en) | 2015-04-22 |
| MX2014015310A (en) | 2015-07-06 |
| IL236226A0 (en) | 2015-01-29 |
| CN104519884A (en) | 2015-04-15 |
| US10016409B2 (en) | 2018-07-10 |
| JPWO2013187075A1 (en) | 2016-02-04 |
| US20160008348A1 (en) | 2016-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408323RA (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
| WO2013186777A3 (en) | Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases | |
| FI3811943T3 (en) | Compound for use in the treatment of ocular disorders | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| PH12017500479B1 (en) | Liquid inhalation formulation comprising rpl554 | |
| EA201101518A1 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY | |
| BR112014014262A2 (en) | nanoparticles; pharmaceutical composition; method of administering one or more therapeutic, prophylactic, and / or diagnostic agents to a patient in need thereof and method of preparing the particles. | |
| EP3015111A4 (en) | Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease | |
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| RU2016106829A (en) | The use of acetyl CoA carboxylase inhibitors for the treatment of acne vulgaris | |
| MX355770B (en) | Pharmaceutical composition of ibuprofen and tramadol for ophthalmological use. | |
| HRP20161389T1 (en) | Pantothenate derivatives for the treatment of neurologic disorders | |
| MX2018001918A (en) | Quantitative peri-orbital application of ophthalmology drugs. | |
| JP2015523986A5 (en) | ||
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| RU2013108390A (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF PERIOPERATIVE ARTERIAL HYPOTENSION IN HUMAN | |
| UA109359C2 (en) | TREATMENT OF SKIN DISEASES AND STATES | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| BR112018072164A2 (en) | pharmaceutical composition, method for treating and / or preventing a patient's skin disease and / or alleviating the symptoms thereof, and cosmetic use of a composition | |
| PH12014502794A1 (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| PH12016500563A1 (en) | 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury | |
| MX2015014939A (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias. | |
| MX2018013474A (en) | Carboxylic acids for early childhood application. |